Search tips
Search criteria 


Logo of neuroncolAboutAuthor GuidelinesEditorial BoardNeuro-Oncology
Neuro-oncol. 2005 January; 7(1): 101–103.
PMCID: PMC1871620


Anyone in the neuro-oncology profession may submit to the journal announcements of meetings, conferences, and funding opportunities of interest to colleagues. Please send announcements to Oliver Bögler, Ph.D., Department of Neurosurgery and Hermelin Brain Tumor Center, 2799 West Grand Boulevard, Detroit, MI 48202, USA (Telephone: 313-916-7293; E-Fax: 425-732-8379; E-mail: gro.cno-oruen-cos@swenyteicos).

Society for Neuro-Oncology Headquarters

Correspondence to the Society should be sent to Society for Neuro-Oncology, Post Office Box 890886, Houston, TX 77289-0886, or in care of Jan Esenwein, 4617 Birch Street, Bellaire, TX 77401-5509, USA (Telephone: 713-349-0952; Fax: 832-201-8129; E-mail: gro.cno-oruen-cos@naj or gro.cno-oruen-cos@pihsrebmem).

Dr. Mark Rosenblum Honored with First Charles Wilson Award

On the occasion of the 20th anniversary of the American Association of Neurological Surgeons/ Congress of Neurological Surgeons (AANS/CNS) Section on Tumors, held at the end of October 2004 in San Francisco at the section’s satellite symposium, Dr. Raymond Sawaya, the current Section Chairman, presented Dr. Mark L. Rosenblum with the first Charles Wilson Award. The award, sponsored by the Brain Tumor Society, recognizes Dr. Rosenblum’s lifelong accomplishments in the brain tumor field and contributions to both the clinical and scientific arenas. Dr. Rosenblum was the founder of the Section on Tumors in 1984 and served as its first chairman. He has remained committed to the ideal of curing brain cancer and currently chairs the Department of Neurosurgery and directs the Hermelin Brain Tumor Center at Henry Ford Hospital, Detroit, Michigan.

House and Senate Appropriations Committees Recommend Increased NIH Attention to Brain Tumor Research

The appropriations committees of the Senate and the House of Representatives have recommended increased funding for the National Institutes of Health, and both the Senate and the House recommended an enhanced commitment by the National Cancer Institute (NCI) to brain tumor research. The House and Senate Appropriations Subcommittees for Labor, Health and Human Services, and Education have filed reports accompanying their different versions of the FY 2004 bills.

The North American Brain Tumor Consortium (NABTC) has joined others in the research community in endorsing the Senate’s Specter-Harkin-Feinstein amendment, and NABTC has urged advocates to contact their senators to request that they vote for the amendment. The Senate subcommittee has also recommended that the National Institute of Neurological Disorders and Stroke (NINDS) collaborate with NCI in carrying out the plan of the Brain Tumor Progress Review Group. The House report also requests that NCI and NINDS file a plan for a coordinated tissue bank within six months of enactment of the bill. The Senate report includes language urging the Centers for Disease Control and Prevention to revise procedures in the cancer registries program to ensure collection of benign brain tumor data, in accordance with the Benign Brain Tumor Cancer Registries Amendment Act. The NABTC is engaged in discussions with NCI and NINDS regarding the actions they will take in response to the directives from Congress. The Senate and House report language is presented below.

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2004. Senate Report 108-81(To Accompany S. 1356). NIH National Cancer Institute. Brain Tumor. In November 2002, the NCI and NINDS convened a panel of experts to review the field of brain tumor research and make recommendations to enhance it. The Committee is pleased that the Institutes followed that meeting by establishing the Neuro-Oncology Branch, an inter-institutional initiative aimed at bringing a multidisciplinary approach to brain tumor research. The Committee now urges the NCI and NINDS to establish a coordinated and multi-institutional tissue bank that would gather not only tissue but also blood and cerebrospinal fluid from patients with all varieties of brain tumors. The system should also be linked to a comprehensive database of relevant clinical, demographic, pathologic, biologic, and therapeutic information on all patients whose tissue is banked. The Committee further strongly urges the NCI to increase funding and the number of Specialized Programs of Research Excellence in Brain Tumors (SPORE) grants in the upcoming fiscal year, with particular emphasis on those proposals which include both basic research and clinical treatment applications.

NIH National Institute of Neurological Disorders and Stroke. Brain Tumors. The Committee continues to be concerned that not enough attention is being given by NINDS to identifying causes of and treatments for brain tumors and encourages NINDS to continue working with NCI to carry out the recommendations of the Report of the Brain Tumor Progress Review Group.

CDC Chronic Disease Prevention and Health Promotion. Cancer Registries. The Committee recognizes the importance of data collection for all brain tumors, including data on malignant and benign brain tumors, through the National Program of Cancer Registries. Comprehensive data collection enhances our understanding of brain tumors and their burden and supports a strong research effort. The Committee commends the CDC for moving forward with implementation of the Benign Brain Tumor Cancer Registries Act in fiscal year 2003 (Public Law 107-260) and strongly urges that adequate funds be provided for benign brain tumor data collection and training in fiscal year 2004.

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2004. House of Representatives Report 108-188 (To accompany H.R. 2660). NIH National Cancer Institute. Brain Tumors. Each year, more than 100,000 new brain tumor cases are diagnosed, including tumors that arise in the brain and tumors that spread to the brain from other cancers such as breast and lung. Cancer is the second leading cause of death in children, and brain tumors are the second most common childhood cancer. The causes of brain tumors remain largely unknown, and there are virtually no means of prevention. Scientists have begun to develop better and less toxic treatments for brain tumors, which will produce longer survival and higher quality of life. The Committee encourages NCI, in cooperation with the National Institute of Neurological Disorders and Stroke, to more fully support brain tumor research, including the brain tumor SPORE grants. The Committee is aware of the ongoing need to develop brain tumor tissue banks and encourages NCI and NINDS to consider developing a plan to establish coordinated tumor banks that would bank not only tissue but also blood and cerebrospinal fluid from patients with all varieties of brain tumors. The Committee requests a copy of the plan within six months of enactment of this bill.


Eleventh Annual Blood-Brain Barrier Consortium Meeting: Delivery of Molecules, Particles, and Cells Across the Blood-Brain Barrier for Diagnosis and/or Treatment of Primary and Metastatic Brain Tumors March 17–19, 2005, Portland, Oregon, USA

Session titles are as follows: BBB Consortium Protocol Discussion, Cell and Molecular Imaging in the CNS, CNS Metastases, Nanotechnology, and Chemoprotection and Chemoenhancement of CNS Disorders. We extend a warm invitation to you to attend these meetings, which are partially funded by NCI, NINDS, and NIDCD.

Contact: Aimee MacKillop

Telephone: 503-494-0614

E-mail: ude.usho@ollikcam

Contact: Nancy Doolittle, R.N., Ph.D.

Telephone: 503-494-5626

E-mail: ude.usho@lttilood

The Blood-Brain Barrier & Neuro-Oncology Program

Oregon Health & Science University

Portland, Oregon

Office of Edward Neuwelt, M.D.

Web site:

World Federation of Neuro-Oncology II/European Association for Neuro-Oncology VI (WFNO-II/EANO-VI) May 5–8, 2005, Edinburgh, United Kingdom

The second quadrennial meeting of the World Federation of Neuro-Oncology, in conjunction with the sixth European Association for Neuro-Oncology meeting (WFNO-II/EANO-VI), will be held at the Edinburgh International Conference Centre in The Exchange district, at the center of Edinburgh. The Advance Programme and the registration and accommodation booking forms for the WFNO-II/EANO-VI conference are available at the Web site. The abstract deadline was December 1, 2004. Online registration is available at the Web site. Early registration ends on January 6, and late registration ends on April 1. The local organizer is R. Grant. See our advertisement in this issue.

Contact: WFNO-II/EANO-VI, Conference Secretariat, Federation of European Cancer, Societies Conference Unit, Avenue E. Mounier 83, B-1200 Brussels, Belgium

Telephone: +32-(0)-2-775-02-04

Fax: +32-(0)-2-775-02-45

E-mail: eb.scef@6ONAE

Web site:

World Federation of Neurosurgical Societies Thirteenth World Congress of Neurological Surgery June 19–24, 2005, Marrakesh, Morocco

The Thirteenth World Congress of Neurological Surgery, coinciding with the fiftieth anniversary of the World Federation of Neurosurgical Societies, will take place in Marrakesh from June 19 to 24, 2005. The congress will be hosted by the Moroccan Society of Neurosurgery and the Pan African Association of Neurological Sciences.

Abdeslam El Khamlichi, M.D., President, Thirteenth World Congress of Neurological Surgery

Abdessamad El Azhari, M.D., Chairman, Scientific Program Committee

Edward R. Laws, M.D., F.A.C.S., President, World Federation of Neurosurgical Societies

Contact: The Congress Secretariat, 13th World, Congress of Neurological Surgery, Hôpital des Spécialités, Department of Neurosurgery, P.O. Box 6444 Rabat-Instituts, Rabat, Morocco

Telephone: 212-37-77-55-61

Fax: 212-37-77-55-64

E-mail: am.ten.mai@hcn2hf, am.ten.mai@hsekarramsnfw, gro.5002hsekarram@ofni

Web site:

Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press